TNF Pharmaceuticals, Inc. (TNFA)
NASDAQ: TNFA · Real-Time Price · USD
0.1538
-0.0253 (-14.13%)
At close: May 21, 2025, 4:00 PM
0.1556
+0.0018 (1.17%)
Pre-market: May 22, 2025, 7:56 AM EDT

TNF Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2018 - 2019
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2018 - 2019
Selling, General & Admin
3.944.165.445.526.422.95
Upgrade
Research & Development
3.793.447.879.076.752.47
Upgrade
Operating Expenses
8.358.6616.3615.2828.28.3
Upgrade
Operating Income
-8.35-8.66-16.36-15.28-28.2-8.3
Upgrade
Interest Expense
-----0.61-1.19
Upgrade
Interest & Investment Income
0.40.350.460.080.010
Upgrade
Other Non Operating Income (Expenses)
-6.84-15.1512.08---
Upgrade
EBT Excluding Unusual Items
-14.79-23.46-3.82-15.2-28.8-9.49
Upgrade
Gain (Loss) on Sale of Investments
000-0-0-
Upgrade
Other Unusual Items
0.10.1-0.180-1.09-
Upgrade
Pretax Income
-14.68-23.36-4-15.2-29.89-9.49
Upgrade
Net Income
-14.68-23.36-4-15.2-29.89-9.49
Upgrade
Preferred Dividends & Other Adjustments
3.413.84.22---
Upgrade
Net Income to Common
-18.1-27.16-8.22-15.2-29.89-9.49
Upgrade
Shares Outstanding (Basic)
322111
Upgrade
Shares Outstanding (Diluted)
322111
Upgrade
Shares Change (YoY)
87.27%57.99%19.18%10.88%24.22%-25.94%
Upgrade
EPS (Basic)
-5.59-11.15-5.33-11.74-25.61-10.10
Upgrade
EPS (Diluted)
-5.59-11.15-5.33-11.74-25.61-10.10
Upgrade
EBITDA
-----28.18-8.28
Upgrade
D&A For EBITDA
----0.020.02
Upgrade
EBIT
-8.35-8.66-16.36-15.28-28.2-8.3
Upgrade
Updated Apr 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q